Table 2 Cohorts of EAC and GAC for immunohistochemistry analysis of CLDN6
EAC (n = 803) | GAC (n = 589) | ||
|---|---|---|---|
n (%) | n (%) | ||
Sex | |||
Male | 706 (87.9) | 397 (67.4) | |
Female | 97 (12.1) | 192 (32.6) | |
Median age (range) | 64 years (28–92 years) | 67 years (18–91 years) | |
pT | |||
pT1 | 141 (17.6) | 81 (13.8) | |
pT2 | 144 (17.9) | 178 (30.2) | |
pT3 | 488 (60.8) | 236 (40.1) | |
pT4 | 30 (3.7) | 94 (15.9) | |
pN | |||
pNx | 4 (0.5) | 1 (0.1) | |
pN0 | 323 (40.2) | 201 (34.1) | |
pN1 + | 476 (59.3) | 387 (66.8) | |
L | |||
Lx | 137 (17.1) | 75 (12.7) | |
L0 | 350 (43.6) | 192 (32.6) | |
L1 | 316 (39.3) | 322 (54.7) | |
V | |||
Vx | 132 (16.4) | 75 (12.7) | |
V0 | 586 (73.0) | 434 (73.7) | |
V1 | 85 (10.6) | 80 (13.6) | |
Pn | |||
Pnx | 131 (16.0) | 75 (12.7) | |
Pn0 | 508 (63.3) | 386 (65.5) | |
Pn1 | 166 (20.7) | 128 (21.7) | |
M | |||
Mx/M0 | 760 (94.65) | 475 (81.6) | |
M1 | 43 (2.8) | 114 (19.4) | |
Neoadjuvant treatmenta | |||
Yes | 514 (36.0) | 195 (33.1) | |
No | 289 (64.0) | 394 (66.9) | |
AJCC Gradeb | |||
NA | 6 (2.1) | 2 (0.5) | |
1 | 2 (0.7) | 3 (0.7) | |
2 | 143 (49.5) | 130 (33.0) | |
3 | 133 (47.7) | 259 (65.8) | |
Her2 status (ERBB) | |||
Amplified | 47 (5.9) | 54 (9.2) | |
Not amplified | 518 (64.5) | 409 (69.4) | |
NA | 238 (29.6) | 126 (21.4) | |
TCGA molecular subtypec | |||
NA | – | 115 (19.5) | |
EBV | – | 24 (4.1 | |
MSI-high | – | 42 (7.1) | |
GS | – | 50 (8.5) | |
CIN | – | 358 (60.8) | |